medigraphic.com
Colegio de Medicina Interna de México.

2007, Número 2

<< Anterior Siguiente >>

Med Int Mex 2007; 23 (2)


Aplicaciones clínicas del ácido tióctico (ácido α-lipoico) en pacientes con neuropatía diabética sintomática: revisión

Cantú BC, Baizábal CF, Aldrete VJ, Chávez GE

Idioma: Español
Referencias bibliográficas: 40
Paginas: 151-158
Archivo PDF: 139.37 Kb.


RESUMEN

La diabetes mellitus es la principal causa de neuropatía en todo el mundo, y para la mayoría de los pacientes padecerla, en alguna de sus formas, es un desenlace común. El ácido tióctico o el ácido α-lipoico y sus derivados, debido a sus propiedades quelantes y antioxidantes, han demostrado su eficacia en el tratamiento de esta complicación. Asimismo, el ácido tióctico también ha demostrado utilidad en el tratamiento de neuropatías resultantes de la terapia antineoplásica con docetaxel y cisplatino.


REFERENCIAS (EN ESTE ARTÍCULO)

  1. Humphey LL, Ballard DJ, Frohnert PP. Chronic renal failure in non-insulin-dependent diabetes mellitus. Ann Inter Med 1989;111:788-96.

  2. Clements R, Bell D. Complications of diabetes. Prevalence detection, current treatment an prognosis. Am J Med 1985;79(5A):2-7.

  3. Rull A. The impact of diabetes mellitus on public health in Mexico. Current Science 1995:64-74.

  4. Greene D, Lattimer S, Sima, A. Sorbitol, phosphoinositides, and sodium-potasium ATPase in the pathogenesis of diabetic complications. N Engl J Medicine 1987;316(10):599- 605.

  5. Ziegler D. Diagnosis, staging and epidemiology of diabetic peripheral neuropathy. Diabetes Nutr Metab 1994;7:342-48.

  6. Boyko EJ, Ahroni JH, Smith DG, Davignon D. Increased mortality associated with diabetic ulcer. Diabet Med 1996;13:967-72.

  7. Zochodne D. Diabetic neuropathies: features and mechanisms. Brain Pathol 1999;9:369-91.

  8. Schmeichel AM, Schmelzer JD, Low PA. Oxidative injury and apoptosis of dorsal root ganglion neurons in chronic experimental diabetic neuropathy. Diabetes 2003;52:165-71.

  9. Greene DA, Sima AA, Stevens MJ, Feldman EL, Lattimer SA. Complications: neuropathy, pathogenetic considerations. Diabetes Care 1992;15:1902-25.

  10. Low PA, Lagerlund TD, McManis PG. Nerve blood flow and oxygen delivery in normal, diabetic, and ischemic neuropathy. Int Rev Neurobiol 1989;31:355-438.

  11. Cameron NE, Cotter MA. Effects of evening primrose oil treatment on sciatic nerve blood flow and endoneurial oxygen tension in streptozotocin-diabetic rats. Acta Diabetol 1994;31:220-25.

  12. Hellweg R, Hartung HD. Endogenous levels of nerve growth factor (NGF) are altered in experimental diabetes mellitus: a possible role for NGF in the pathogenesis of diabetic neuropathy. J Neurosci Res 1990;26:258-67.

  13. Rull JA y colaboradores. Cambios histológicos y funcionales. En: Consenso sobre neuropatía diabética. Grupo Nacional de Consenso en Diabetes. Fundación Mexicana para la Salud. México, 1996.

  14. Otero-Siliceo E, Ruano-Calderón L. Neuropatía diabética: ¿una enfermedad vascular? Rev Neurol 2003;37(7): 658-61.

  15. Schultz J, Harris AK, Rychly D, Ergul A. Oxidative stress and the use of antioxidants in diabetes: Linking basic science to clinical practice. Card Diabetology 2005;4:5.

  16. Martínez-Conde A, Paredes FC, Zacarías CR. Neuropatía diabética. Rev Hosp Gral M Gea González 2002;5(1 y 2): 7-23.

  17. Aldrete-Velasco J y col. Correlación entre nefropatía, neuropatía y retinopatía en pacientes con diabetes mellitus no insulinodependiente. Rev Asoc Med Intern de México 1995;11(3):109-14.

  18. Aldrete VJ, Morales SJ, Villicaña MH, Aldrete JA y col. Eficacia clínica y neurofisiológica del tolrestato en pacientes con neuropatía diabética avanzada. Rev Med Int Méx 1995;11(4):160-7.

  19. Effect of intensive treatment on nerve conduction in the Diabetes Control and Complication Trial. Ann Neurol 1995;38:869-80

  20. The Diabetes Control and Complications Trial Research Group. The effect of intensive diabetes therapy on the development and progression of neuropathy. Ann Int Med 1995;122:561-66.

  21. Snell EE, Strong FM, Peterson WH. Growth factors for bacteria. Fractionation and properties of an accessory factor for lactic acid bacteria. Biochem J 1937;31:1789.

  22. Reed LJ, DeBusk BG, Gunsalus IC, Hornberger CS. Crystalline α-lipoic acid: a catalytic agent associated with pyruvate dehydrogenase. Science 1951;114:93-103.

  23. Reed LJ. The chemistry and function of lipoic acids. Adv Enzymol 1957;18:319-47.

  24. Carreau JP. Biosynthesis of lipoic acid via unsaturated fatty acids. Meth Enzymol 1979;62:152-58.

  25. Jordan SW, Cronan JE. Biosynthesis of lipoic acid and posttranslational modification with lipoic acid in Escherichia coli. Methods Enzymol 1997;279:176.

  26. Biewenga GP, Haenen GR, Bast A. The pharmacology of the antioxidant lipoic acid. Gen Pharmac 1997;29(3):315-31.

  27. Teichert J, Kern J, Tritschler HJ, Ulrich H, Preiss R. Investigations on the pharmacokinetics of alpha-lipoic acid in healthy volunteers. Int J Clin Pharmacol Ther 1998;36:625.

  28. Spence JT, McCormick DB. Lipoic acid metabolism in the rat. Arch Biochem Biphys 1976;174:13.

  29. Biewenga G, Haenen GR, Bast A. The role of lipoic acid metabolism in the treatment of diabetic polyneuropathy. Drug Metab Rev 1997;29:1025.

  30. Nagamatsu M, Nickander KK, Schmelzer JD, et al. Lipoic acid improves nerve blood flow, reduces oxidative stress and improves distal nerve conduction in experimental diabetic neuropathy. Diabetes Care 1995;18:1160-67.

  31. Ziegler D, Hanefeld MH, Ruhnau KJ, et al. Treatment of symptomatic diabetic polyneuropathy with the antioxidant alipoic acid. A 7-month multicenter randomized controlled trial (ALADIN III Study). Diabetes Care 1999;22:1296-1301.

  32. Ametov S, Barinov A, Dyck PJ, et al. The sensory symptoms of diabetic polyneuropathy are improved with [alpha]-lipoic acid: The SYDNEY Trial. Diabetes Care 2003;26:770-76.

  33. Ziegler D, Nowak H, Kempler P, Vargha P, Low PA. Treatment of symptomatic diabetic polyneuropathy with the antioxidant [alpha]-lipoic acid: a meta-analysis. Diabetic Medicine 2004;21:114-21.

  34. Ziegler D, Schatz H, Conrad F, Gries FA, et al. Effects of treatment with the antioxidant alpha-lipoic acid on cardiac autonomic neuropathy in NIDDM patients: A 4-month randomized controlled multicenter trial (DEKAN Study). Diabetes Care 1997;20:369-73.

  35. Strodter D, Lehmann E, Lehmann U, Tritschler HJ, et al. The influence of thioctic acid on metabolism and function of the diabetic heart. Diabetes Res Clin Pract 1995;29:19-26.

  36. Ziegler D. Diabetic cardiovascular autonomic neuropathy: prognosis, diagnosis and treatment. Diabetes Metab Rev 1994;10:339-83.

  37. Gedlicka GV, Kornek K, Schmid WS. Amelioration of docetaxel/ cisplatin induced polyneuropathy by alpha-lipoic acid. Ann Oncol 2003;14:339-40.

  38. Postma TJ, Heimans JJ. Grading of chemotherapy-induced peripheral neuropathy. Ann Oncol 2000;11:509-13.

  39. Culy CR, Clemett D, Wiseman LR. Oxaliplatin: A review of its pharmacological properties and clinical efficacy in metastatic colorectal cancer and its potential in other malignancies. Drugs 2000;60:895-924.

  40. Gedlicka C, Scheithauer W, Schull B, Kornek GV. Effective treatment of oxaliplatin-induced cumulative polyneuropathy with alpha-lipoic acid. J Clin Oncol 2002;20(15):3359-61.




2020     |     www.medigraphic.com